Welcome to our dedicated page for Scholar Rock Holding news (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding stock.
News about Scholar Rock Holding Corporation (NASDAQ: SRRK) focuses on its progress as a late-stage biopharmaceutical company in neuromuscular diseases, particularly spinal muscular atrophy (SMA). Company announcements highlight clinical, regulatory, financial, and corporate developments tied to its myostatin biology platform and lead investigational therapy, apitegromab.
Investors and followers of SRRK can expect regular updates on the regulatory path for apitegromab, including interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Recent press releases describe a Biologics License Application (BLA) for apitegromab, a Complete Response Letter related to a third-party fill-finish facility, a subsequent Type A meeting with the FDA, and ongoing EMA review of a Marketing Authorisation Application. News items also cover disease awareness and launch readiness activities in the United States and Europe.
Scholar Rock’s news flow also includes clinical trial milestones across its pipeline. Examples include dosing in the Phase 2 OPAL study in infants and toddlers with SMA, plans for the FORGE Phase 2 trial in facioscapulohumeral muscular dystrophy (FSHD), completion of a subcutaneous apitegromab Phase 1 study, and initiation of a Phase 1 trial of SRK-439 in healthy volunteers. These updates provide insight into the company’s broader anti-myostatin program and expansion into additional rare, severe, and debilitating neuromuscular diseases.
Financial and corporate news for SRRK features quarterly financial results, cash runway commentary, equity offerings under at-the-market programs, and inducement equity grants to new employees under the 2022 Inducement Equity Plan. Scholar Rock also issues announcements about participation in major healthcare conferences and investor events. For readers tracking SRRK stock and the company’s evolution as a late-stage biopharmaceutical organization, this news page aggregates these developments in one place.
Scholar Rock (NASDAQ: SRRK) has announced new quality-of-life data from its Phase 2 TOPAZ trial extension, indicating sustained improvements in daily activities, fatigue, and muscle endurance for non-ambulatory patients with spinal muscular atrophy (SMA) over 24 months. Data presented in Barcelona suggest apitegromab may offer significant benefits, particularly for patients receiving nusinersen. No safety concerns were reported, with the majority of patients opting to continue treatment into a 36-month extension.
Scholar Rock (NASDAQ: SRRK) announced the upcoming presentation of data from the DRAGON Phase 1 clinical trial of SRK-181 at the SITC Annual Meeting in Boston, from November 8-12. The study focuses on patients with advanced solid tumors, showcasing safety, efficacy, and biomarker results from Part A and an update on Part B.
SRK-181 is designed to overcome resistance to checkpoint inhibitors, with potential benefits in tumor response and survival rates. The trial continues to enroll patients across multiple cancer types, demonstrating a promising path for future cancer therapies.
Scholar Rock (NASDAQ: SRRK) announced that new data from the Phase 2 TOPAZ trial extension for apitegromab will be presented at two upcoming conferences. The presentations, scheduled for October 12 in Halifax and October 22 in Barcelona, will focus on multiple efficacy endpoints after 24 months of treatment for spinal muscular atrophy (SMA). Apitegromab is the first selective myostatin inhibitor showing positive proof of concept in SMA. The FDA has granted several designations to apitegromab, highlighting its potential in treating this serious condition.
Scholar Rock (NASDAQ: SRRK) announced the granting of a stock option to Jay Backstrom, M.D., M.P.H., as an employment inducement. The award, part of the 2022 Inducement Plan, involves 1,000,000 shares at an exercise price of $8.85, which will vest over four years. This plan, approved on June 16, 2022, allows for equity awards to new hires or those returning after a break in employment. Scholar Rock focuses on biopharmaceutical developments targeting serious diseases influenced by protein growth factors.
Scholar Rock has appointed Dr. Jay Backstrom as CEO-Elect, effective September 20, 2022. With over 30 years of biopharmaceutical leadership, he previously held roles at Acceleron and Celgene, contributing to drug development and approval processes. Nagesh Mahanthappa will serve as interim CEO during the transition until October 20, 2022. Dr. Backstrom aims to advance the company’s clinical programs targeting spinal muscular atrophy and oncology, emphasizing growth milestones and innovative therapy approaches.
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company, announced two upcoming presentations at major conferences on September 25-29, focusing on SRK-181, a selective inhibitor aimed at overcoming cancer therapy resistance. At the ACCP Annual Meeting, new pharmacokinetic data will be presented, while the World Clinical Biomarkers & CDx Summit will discuss biomarker strategies and early clinical data. These presentations will be available on Scholar Rock's website post-conference.
Scholar Rock (NASDAQ: SRRK) reported positive 24-month data from its Phase 2 TOPAZ trial, supporting apitegromab's potential for Spinal Muscular Atrophy (SMA) patients. The company is actively enrolling for its pivotal Phase 3 SAPPHIRE trial. Financially, Scholar Rock completed a $205 million direct offering, strengthening its balance sheet, while net loss widened to $44 million for Q2 2022, with revenues dropping to $0 from $4.6 million a year prior. R&D expenses increased due to higher clinical costs for apitegromab.
Scholar Rock (NASDAQ: SRRK) has appointed Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, to its Board of Directors as an independent director. With over 20 years in biotechnology investment, Dr. Akkaraju brings extensive experience to the company as it develops its late-stage pipeline and discovery programs. His addition is anticipated to enhance Scholar Rock's strategic direction, particularly in advancing its therapeutic candidate for spinal muscular atrophy amid ongoing Phase 3 trials.
Scholar Rock (NASDAQ: SRRK) announced its participation in the ‘Muscle Beach’ panel at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:20 PM ET. This clinical-stage biopharmaceutical company focuses on developing treatments for serious diseases reliant on protein growth factors. A live webcast of the event will be available on their website, with an archived replay accessible for 90 days post-event.
Scholar Rock (NASDAQ: SRRK) announced new data on its selective TGFβ1 antibody, which inhibits proTGFβ1 activation linked to extracellular matrix proteins. This data shows reduced TGFβ1 signaling and fibrosis in preclinical models, suggesting a safe treatment for fibrotic diseases like Alport syndrome and scleroderma. The findings will be presented at the 2022 FASEB Science Research Conference in Ireland on July 21, highlighting Scholar Rock's innovative approach to treating serious diseases driven by protein growth factors.